So, in a world where "malaria vaccine" might sound like a savior for African children, we're left wondering if the Mosquirix vaccine is the real deal or just another plot twist in Bill Gates's grand biometric adventure. Who needs a crystal ball when you have biometric tracking? More on this below. Keep reading if you dare to unlock the mysteries of the Mosquirix!
Bill Gates, in collaboration with the World Economic Forum (WEF), has unveiled a plan to administer a new malaria vaccine, Mosquirix, to African children using cutting-edge biometric tracking technology. While this initiative aims to combat malaria, it has raised concerns about the vaccine's effectiveness and potential side effects.
Introduction: Bill Gates and the WEF have joined forces to combat malaria in Africa by introducing the Mosquirix vaccine. However, some critics argue that this vaccine may not be as effective as it seems and could have adverse effects on children.
Biometric Tracking and Vaccination: Under this initiative, biometric tracking technology will be employed to monitor the distribution of the Mosquirix vaccine. This technology allows for precise record-keeping and ensures that children receive the necessary doses.
Vaccine Effectiveness: One of the key concerns surrounding Mosquirix is its effectiveness. Studies have shown that only the fourth dose of the vaccine provides a modest 32% effectiveness in preventing severe malaria. This raises questions about the vaccine's ability to protect children from the disease's worst outcomes.
Meningitis Risk: What makes Mosquirix particularly controversial is its potential to cause meningitis in young children. Some studies have reported cases of meningitis following vaccination, with an incidence rate of 2.5 cases per 1000 doses of the vaccine. Given that four doses are recommended, there is concern that approximately one out of 100-150 children receiving the vaccine may develop meningitis.
Malaria vs. Meningitis Risk: The trade-off between preventing malaria and the risk of meningitis is a critical consideration. Mosquirix's effectiveness wanes over time, much like some COVID-19 vaccines, making vaccinated children more susceptible to malaria after several years. This raises questions about whether the vaccine truly benefits the child and their family in the long run.
Bill Gates's Biometric Investments: Critics argue that Bill Gates's investments in biometric technology, such as Simprints, raise questions about the true motives behind this vaccination initiative. They speculate whether this project serves as a means to promote biometric solutions for controlling third-world citizens.
We need your help to continue to post news that matters...You can support our efforts by buying us a coffee... It’s quick, secure, and easy. https://gogetfunding.com/realnewscast/